Cargando…
Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae
In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for Enterobacteriaceae from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP breakpoint are insuffic...
Autores principales: | Park, Ga Eun, Ko, Jae-Hoon, Cho, Sun Young, Huh, Hee Jae, Baek, Jin Yang, Ko, Kwan Soo, Kang, Cheol-In, Chung, Doo Ryeon, Peck, Kyong Ran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074352/ https://www.ncbi.nlm.nih.gov/pubmed/33924153 http://dx.doi.org/10.3390/antibiotics10040469 |
Ejemplares similares
-
Comparing the Synergistic and Antagonistic Interactions of Ciprofloxacin and Levofloxacin Combined with Rifampin against Drug-Resistant Staphylococcus aureus: A Time–Kill Assay
por: Kang, Yu Ri, et al.
Publicado: (2023) -
Epidemiology of Ciprofloxacin Resistance and Its Relationship to Extended-Spectrum β-Lactamase Production in Proteus mirabilis Bacteremia
por: Sohn, Kyung Mok, et al.
Publicado: (2011) -
Difference in the Clinical Outcome of Bloodstream Infections Caused by Klebsiella aerogenes and Enterobacter cloacae Complex
por: Jeon, Minji, et al.
Publicado: (2021) -
Clinical Impact of Revised Cefepime Breakpoint in Patients With Enterobacteriaceae Bacteremia
por: Foong, Kap Sum, et al.
Publicado: (2019) -
Severe Thrombocytopenia in a Patient with COVID-19
por: Nham, Eliel, et al.
Publicado: (2020)